Worth Watching: Today Foamix Pharmaceuticals Ltd Stock Crashes

Worth Watching: Today Foamix Pharmaceuticals Ltd Stock Crashes

The stock of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) is a huge mover today! The stock decreased 5.11% or $0.45 on November 15, hitting $8.35. About 117,475 shares traded hands or 13.08% up from the average. Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has risen 32.33% since April 13, 2016 and is uptrending. It has outperformed by 28.40% the S&P500.
The move comes after 9 months negative chart setup for the $307.70 million company. It was reported on Nov, 15 by Barchart.com. We have $7.26 PT which if reached, will make NASDAQ:FOMX worth $40.00M less.

According to Zacks Investment Research, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel.”

More important recent Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) news were published by: Prnewswire.com which released: “Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary …” on September 27, 2016, also Prnewswire.com published article titled: “Foamix Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare …”, Marketwatch.com published: “/quotes/zigman/3870025/realtime” on September 19, 2014. More interesting news about Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) was released by: Quotes.Wsj.com and their article: “News Foamix Pharmaceuticals Ltd.FOMX” with publication date: September 13, 2014.

FOMX Company Profile

Foamix Pharmaceuticals Ltd., incorporated on January 19, 2003, is a clinical-stage specialty pharmaceutical company. The Firm is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Firm operates in the segment of development and commercialization of foam formulations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment